What should sponsors evaluate when identifying risks in a clinical trial?

• A. The aesthetic appearance of the trial documents
• B. The speed of enrollment
• C. The cost of risk mitigation
• D. Likelihood of harm/hazard occurring, detectability, and impact on participant protection and trial results

Answer: (D)

In risk identification for a clinical trial, focus on what could harm participants or affect the validity of the study. The sponsor should evaluate three interrelated elements: how likely the hazard is to occur, how easily the risk could be detected if it happens, and the potential impact on participant protection and on the trial results. This combination helps prioritize which risks need safeguards and closer monitoring, because a risk that is likely to occur, would have a significant effect if it happens, and isn’t easy to detect poses the greatest threat and requires proactive controls. The other options don’t address the core of risk assessment: aesthetic aspects of documents, enrollment speed, or the cost of mitigating actions don’t define the risk itself or its potential impact on safety and data quality. By concentrating on likelihood, detectability, and impact, sponsors can design appropriate safeguards, monitoring plans, and contingency strategies to protect participants and ensure credible results.